Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...
A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...
Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...
We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...
3h
DelveInsight's "ROCKLATAN/ROCLANDA Market Size, Forecast, and Market Insight Report" highlights the details around ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback